AquaBounty (NASDAQ:AQB) started trading on the Nasdaq in January 2017 and it was actually a spinoff stock from Intrexon (XON) that today is named Precigen (PGEN), a biotechnology company. When it was under the name Intrexon it was managed by Randal. J. Kirk who is today a major shareholder in AQB and I will elaborate on him later. The beginning for AquaBounty on Nasdaq was not an easy one and immediately after it started trading, the stock was under pressure and investors didn’t see much opportunity in the company.
On the first day of trading it went up to $30 and then started to drop, by the end of 2017 it already was trading at around $3 (90% drop in share price). Since then it mostly stayed at a range of $1.50-$3.00 and probably bottomed on March 2020 where money started flowing into the stock.
In this article I would like to provide an overview of the company and try to give a sense of why this stock started its move and why it might be worthwhile to join in.
Source - www.tradingview.com
Who are you AquaBounty?
AquaBounty's product is the AquaAdvantage (AAS) fish which is actually an Atlantic Salmon fish that was genetically engineered. It was developed in 1989 by researchers at the Memorial University in Canada. They altered the growth hormone, which led to accelerated growth and is grown to at least 4KG in size, which is the harvest size for salmon fish in a timeframe of approximately 18 months, compared to a period of between 24-36 months of a regular Atlantic Salmon.
Moreover, this fish requires 25% less feeding. According to AquaBounty both those elements of less feeding and accelerated growth (meaning a shortened period of time to market) can drastically increase the topline measures such as profit and can double the
